{"id":"W3080424252","doi":"10.1136/esmoopen-2020-000714","title":"Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK; Exelixis","keywords":"Sorafenib; Cabozantinib; Medicine; Placebo; Hepatocellular carcinoma; Internal medicine; Clinical endpoint; Subgroup analysis; Population; Oncology; Gastroenterology; Randomized controlled trial; Surgery; Confidence interval; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003878783,0.001652768,0.00571407,0.0008200289,0.000326222,0.001419569,0.0007076936,0.00115704,0.002897204],"category_scores_gemma":[0.004215566,0.0004094308,0.01377688,0.0009566119,0.0003318125,0.000582514,0.0006752232,0.001391914,0.0003007144],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007833152,"about_ca_system_score_gemma":0.0009310711,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001624464,"about_ca_topic_score_gemma":0.004463752,"domain_scores_codex":[0.9975061,0.001220652,0.0003954309,0.0004070944,0.0002368174,0.0002338928],"domain_scores_gemma":[0.9982388,0.0006192754,0.0005021769,0.0002987136,0.0001331578,0.0002078596],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.8047359,0.0004201613,0.02788159,0.004209346,0.1311989,0.0005634597,0.000155111,0.0009935767,0.004580264,0.0001478289,0.001840135,0.02327367],"study_design_scores_gemma":[0.4672211,0.03208876,0.2007825,0.001082441,0.2824269,0.001248794,0.0004633184,0.003703922,0.003124736,0.001427549,0.00624971,0.0001803337],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9170637,0.07497639,0.001082144,0.0007723027,0.0007701588,0.0008246545,0.003018054,0.00008760217,0.001404886],"genre_scores_gemma":[0.9923882,0.003723495,0.0003142361,0.0003558626,0.0003228938,0.000420915,0.001796797,0.00002277928,0.0006549062],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00571407,"threshold_uncertainty_score":0.02051324,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1231581948242682,"score_gpt":0.3314540554563082,"score_spread":0.20829586063204,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}